Journal of Evolutionary Economics

, Volume 27, Issue 4, pp 691–727 | Cite as

Determinants of pharmaceutical innovation: the role of technological opportunities revisited

Regular Article
  • 174 Downloads

Abstract

Recent empirical contributions emphasize the importance of (potential) market size for the development of new pharmaceuticals. At the same time, many scholars point out the importance of scientific advances for the industry’s R&D activities. Against this background I analyze the relationship between (potential) market size, technological opportunities, and the number of new pharmaceuticals in the United States. Technological opportunities are operationalized as growth rates of the relevant knowledge stock, as proposed by Andersen (Struct Chang Econ Dyn 9(1):5–34 1998, J Evol Econ 9(4):487–526 1999). I analyze a unique dataset by using an “entry stock” Poisson quasi-maximum likelihood estimator. The results reveal a rather robust and significantly positive response of the number of new pharmaceuticals, i.e., new molecular entities or new drug approvals, to market size and technological opportunities.

Keywords

Determinants of innovation Pharmaceuticals Demand Technological opportunities 

JEL Classification

O31 J10 J20 L65 

Notes

Acknowledgements

I am grateful to the German Research Foundation (DFG) for financial support (DFG GKR 1411). I thank Uwe Cantner, Matthew J. Higgins, Ivan Savin, Simon Wiederhold, the participants of the Research Seminar at the Institute for Innovation and Entrepreneurship in Gothenburg, Sweden on February the 3rd 2012, the participants of the DRUID Society Conference 2012 in Copenhagen, Denmark, the participants of the 14th ISS Conference in Brisbane, Australia, the participants of the Annual Congress of the Verein für Socialpolitik 2012 in Göttingen, Germany and two anonymous reviewers for useful comments, expressed interest and concerns. The usual caveats apply.

Compliance with Ethical Standards

Conflict of interests

The author declares that he has no conflict of interest.

References

  1. Acemoglu D, Linn J (2004) Market size in innovation: theory and evidence from the pharmaceutical industry. Quart J Econom 119(3):1049–1090CrossRefGoogle Scholar
  2. Adner R, Levinthal D (2001) Demand heterogeneity and technology evolution: implications for product and process innovation. Manag Sci 47(5):611–628CrossRefGoogle Scholar
  3. Andersen B (1998) The evolution of technological trajectories 1890–1990. Struct Chang Econ Dyn 9(1):5–34CrossRefGoogle Scholar
  4. Andersen B (1999) The hunt for s-shaped growth paths in technological innovation: a patent study. J Evol Econ 9(4):487–526CrossRefGoogle Scholar
  5. Azoulay P (2004) Capturing knowledge within and across firm boundaries: evidence from clinical development. Am Econ Rev 94(5):1591–1612CrossRefGoogle Scholar
  6. Barge-Gil A, López A (2014) R&D determinants: accounting for the differences between research and development. Res Policy 43(9):1634–1648CrossRefGoogle Scholar
  7. Becker W, Peters J (2000) Technological opportunities, absorptive capacities, and innovation. Discussion Paper Series, University of Augsburg, Institute for Economics, p 195Google Scholar
  8. Bitzer J, Stephan A (2007) A Schumpeter-inspired approach to the construction of R&D capital stocks. Appl Econ 39(2):179–189CrossRefGoogle Scholar
  9. Blundell R, Griffith R, Reenen JV (1995) Dynamic count data models of technological innovation. Econ J 105(429):333–344CrossRefGoogle Scholar
  10. Blundell R, Griffith R, Windmeijer F (2002) Individual effects and dynamics in count data models. J Econ 108(1):113–131CrossRefGoogle Scholar
  11. Cameron AC, Trivedi PK (2013) Regression analysis of count data, 2nd edn. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  12. Castellacci F (2007) Technological regimes and sectoral differences in productivity growth. Ind Corp Chang 16(6):1105–1145CrossRefGoogle Scholar
  13. Cerda RA (2007) Endogenous innovations in the pharmaceutical industry. J Evol Econ 17(4):473–515CrossRefGoogle Scholar
  14. Cockburn IM, Henderson RM (2001) Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. J Health Econ 20(6):1033–1057CrossRefGoogle Scholar
  15. Cohen WM, Levin RC (1989) Empirical studies of innovation and market structure. In: Schmalensee R, Willig R (eds) Handbook of industrial organization. Elsevier, Amsterdam, pp 1059–1107Google Scholar
  16. Cohen WM, Levinthal DA (1989) Innovation and learning: the two faces of R&D. Econ J 99(397):569–596CrossRefGoogle Scholar
  17. Cohen WM, Levin RC, Mowery DC (1987) Firm size and R&D intensity: a re-examination. J Ind Econ 35(4):543–565CrossRefGoogle Scholar
  18. Cohen W, Nelson R, Walsh J (2002) Links and impacts: the influence of public research on industrial R&D. Manag Sci 48(1):1–23CrossRefGoogle Scholar
  19. DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econ 28(4-5):469–479CrossRefGoogle Scholar
  20. Dosi G (1988) Sources, procedures, and microeconomic effects of innovation. J Econ Lit 26(3):1120–1171Google Scholar
  21. Fabrizio KR, Thomas LG (2012) The impact of local demand on innovation in a global industry. Strateg Manag J 33(1):42–64CrossRefGoogle Scholar
  22. Food and Drug Administration (FDA) (2011) Old NDC Database information. http://www.fda.gov/Drugs/InformationOnDrugs/ucm257245.htm, visited on June 18, 2013
  23. Freeman C (1994) The economics of technical change. Camb J Econ 18 (5):463–514CrossRefGoogle Scholar
  24. Galambos L, Sturchio JL (1998) Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation. Bus Hist Rev 72(2):250–278CrossRefGoogle Scholar
  25. Gambardella A (1995) Science and innovation: the U.S. pharmaceutical industry during the 1980s. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  26. Geroski PA, Walters CF (1995) Innovative activity over the business cycle. Econ J 105(431):916–928CrossRefGoogle Scholar
  27. Giaccotto C, Santerre RE, Vernon JA (2005) Drug prices and research and development investment behavior in the pharmaceutical industry. J Law Econ 48(1):195–214CrossRefGoogle Scholar
  28. Godin B (1996) Research and the practice of publication in industries. Res Policy 25(4):587–606CrossRefGoogle Scholar
  29. Gourieroux C, Monfort A, Trognon A (1984) Pseudo maximum likelihood methods: applications to poisson models. Econometrica 52(3):701–720CrossRefGoogle Scholar
  30. Grabowski HG (1968) The determinants of industrial research and development: a study of the chemical, drug, and petroleum industries. J Polit Econ 76(2):292–306CrossRefGoogle Scholar
  31. Grabowski H, Vernon J (2000) The determinants of pharmaceutical research and development expenditures. J Evol Econ 10(1–2):201–215CrossRefGoogle Scholar
  32. Grabowski HG, Wang YR (2006) The quantity and quality of worldwide new drug introductions 1982–2003. Health Aff 25(2):452–460CrossRefGoogle Scholar
  33. Grabowski HG, Vernon JM, Thomas LG (1978) Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry. J Law Econ 21(1):133–163CrossRefGoogle Scholar
  34. Griliches Z, Hall BH, Pakes A (1991) R&D, patents, and market value revisited: is there a second (technological opportunity) factor? Econ Innov New Technol 1(3):183–201CrossRefGoogle Scholar
  35. Hamilton KS (2003) Subfield and level classification of journals. CHI Research Inc., CHI No. 2012-RGoogle Scholar
  36. Henderson R, Cockburn I (1994) Measuring competence? Exploring firm effects in pharmaceutical research. Strateg Manag J 15:63–84CrossRefGoogle Scholar
  37. Jaffe AB (1986) Technological opportunity and spillovers of R&D: evidence from firms’ patents, profits, and market value. Am Econ Rev 76(5):984–1001Google Scholar
  38. Jaffe AB (1989a) Characterizing the ’technological position’ of firms, with application to quantifying technological opportunity and research spillovers. Res Policy 18(2):8–97CrossRefGoogle Scholar
  39. Jaffe AB (1989b) Real effects of academic research. Am Econ Rev 79(5):957–970Google Scholar
  40. Kleinknecht A, Verspagen B (1990) Demand and innovation: Schmookler re-examined. Res Policy 19(4):387–394CrossRefGoogle Scholar
  41. Klevorick AK, Levin RC, Nelson RR, Winter SG (1995) On the sources and significance of interindustry differences in technological opportunities. Res Policy 24(2):185–205CrossRefGoogle Scholar
  42. Kneller R (2010) The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 9(11):867–882CrossRefGoogle Scholar
  43. Kremer M (2002) Pharmaceuticals and the developing World. J Econ Perspect 16(4):67–90CrossRefGoogle Scholar
  44. Lacy C, Armstrong L, Goldman M, Lance L (eds) (2010) Drug information handbook, 19th edn. Lexi-Comp, HudsonGoogle Scholar
  45. Levin RC, Cohen WM, Mowery DC (1985) R&D appropriability, opportunity, and market structure: new evidence on some Schumpeterian hypotheses. Am Econ Rev 75(2):20–24Google Scholar
  46. Levin RC, Klevorick AK, Nelson RR, Winter SG, Gilbert R, Griliches Z (1987) Appropriating the returns from industrial research and development. Brook Pap Econ Act 1987(3):783–831CrossRefGoogle Scholar
  47. Lichtenberg FR (2004) Sources of U.S. longevity increase, 1960–2001. Q Rev Econ Fin 44(3):369–389CrossRefGoogle Scholar
  48. Lichtenberg FR (2005a) Pharmaceutical innovation and the burden of disease in developing and developed countries. J Med Philos 30(6):663–690CrossRefGoogle Scholar
  49. Lichtenberg FR (2005b) The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. Int J Health Care Fin Econ 5(1):47–73CrossRefGoogle Scholar
  50. Lim K (2004) The relationship between research and innovation in the semiconductor and pharmaceutical industries (1981-1997). Res Policy 33(2):287–321CrossRefGoogle Scholar
  51. Mahlich JC, Roediger-Schluga T (2006) The determinants of pharmaceutical R&D expenditures: evidence from Japan. Rev Ind Organ 28(2):145–164CrossRefGoogle Scholar
  52. Malerba F, Nelson R, Orsenigo L, Winter S (2007) Demand, innovation, and the dynamics of market structure: the role of experimental users and diverse preferences. J Evol Econ 17(4):371–399CrossRefGoogle Scholar
  53. Mansfield E (1991) Academic research and industrial innovation. Res Policy 20(1):1–12CrossRefGoogle Scholar
  54. McKelvey M (1996) Evolutionary innovations: the business of biotechnology. Oxford University Press, OxfordGoogle Scholar
  55. Morton FMS (1999) Entry decisions in the generic pharmaceutical industry. RAND J Econ 30(3):421–440CrossRefGoogle Scholar
  56. Mowery D, Rosenberg N (1979) The influence of market demand upon innovation: a critical review of some recent empirical studies. Res Policy 8(2):102–153CrossRefGoogle Scholar
  57. Narin F, Olivastro D (1992) Status report: linkage between technology and science. Res Policy 21(3):237–249CrossRefGoogle Scholar
  58. Narin F, Rozek RP (1988) Bibliometric analysis of U.S. pharmaceutical industry research performance. Res Policy 17(3):139–154CrossRefGoogle Scholar
  59. Nelson RR (1988) Modelling the connections in the cross section between technical progress and R&D intensity. RAND J Econ 19(3):478–485CrossRefGoogle Scholar
  60. Nelson RR, Wolff EN (1997) Factors behind cross-industry differences in technical progress. Struct Chang Econ Dyn 8(2):205–220CrossRefGoogle Scholar
  61. Pan W (2001) Akaike’s information criterion in generalized estimating equations. Biometrics 57(1):120–125CrossRefGoogle Scholar
  62. Rasmussen B (2010) Innovation and commercialisation in the biopharmaceutical industry: creating and capturing value. Edward Elgar Publishing Ltd, Cheltenham and NorthhamptonCrossRefGoogle Scholar
  63. Reiffen D, Ward MR (2005) Generic drug industry dynamics. Rev Econ Stat 87(1):37–49CrossRefGoogle Scholar
  64. Scherer FM (1965) Firm size, market structure, opportunity, and the output of patented inventions. Am Econ Rev 55(5):1097–1125Google Scholar
  65. Scherer FM (1982) Demand-pull and technological invention: Schmookler revisited. J Ind Econ 30(3):225–237CrossRefGoogle Scholar
  66. Schmookler J (1966) Invention and economic growth. Harvard University Press, CambridgeCrossRefGoogle Scholar
  67. Toole A (2007) Does public scientific research complement private investment in research and development in the pharmaceutical industry? J Law Econ 50(1):81–104CrossRefGoogle Scholar
  68. Toole AA (2012) The impact of public basic research on industrial innovation: evidence from the pharmaceutical industry. Res Policy 41(1):1–12CrossRefGoogle Scholar
  69. von Hippel E (1976) The dominant role of users in the scientific instrument innovation process. Res Policy 5(3):212–239CrossRefGoogle Scholar
  70. Walsh V (1984) Invention and innovation in the chemical industry: demand-pull or discovery-push? Res Policy 13(4):211–234CrossRefGoogle Scholar
  71. Yin W (2008) Market incentives and pharmaceutical innovation. J Health Econ 27(4):1060–1077CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Chair of Organization, Technology Management and Entrepreneurship (OTE)University of PassauPassauGermany

Personalised recommendations